Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment

被引:19
|
作者
Kleinendorst, Simone C. [1 ]
Oosterwijk, Egbert [2 ]
Bussink, Johan [3 ]
Westdorp, Harm [4 ,5 ]
Konijnenberg, Mark W. [1 ]
Heskamp, Sandra [1 ,6 ]
机构
[1] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Med Imaging, Med Ctr,Nucl Med, Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Urol, Med Ctr, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Dept Radiat Oncol, Med Ctr, Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Tumor Immunol, Med Ctr, Nijmegen, Netherlands
[5] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands
基金
荷兰研究理事会;
关键词
ANTITUMOR IMMUNITY; MOUSE MODEL; RADIATION; IMMUNOTHERAPY; COMBINATION; BLOCKADE; LU-177-DOTATATE; THERANOSTICS; RADIOTHERAPY; RADIUM-223;
D O I
10.1158/1078-0432.CCR-21-4332
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The development of immunotherapy, in particular immune checkpoint inhibitors (ICI), has revolutionized cancer treatment in the past decades. However, its efficacy is still limited to subgroups of patients with cancer. Therefore, effective treatment combination strategies are needed. Here, radiotherapy is highly promising, as it can induce immunogenic cell death, triggering the release of pro-inflammatory cytokines, thereby creating an immunogenic pheno-type and sensitizing tumors to ICI. Recently, targeted radionuclide therapy (TRT) has attained significant interest for cancer treatment. In this approach, a tumor-targeting radiopharmaceutical is used to specifically deliver a therapeutic radiation dose to all tumor cells, including distant metastatic lesions, while limiting radiation expo-sure to healthy tissue. However, fundamental differences between TRT and conventional radiotherapy make it impossible to directly extrapolate the biological effects from conventional radiotherapy to TRT. In this review, we present a comprehensive overview of studies investigating the immunomodulatory effects of TRT and the efficacy of combined TRT-ICI treatment. Preclinical studies have evaluated a variety of murine cancer models in which a- or (3-emitting radionuclides were directed to a diverse set of targets. In addition, clinical trials are ongoing to assess safety and efficacy of combined TRT-ICI in patients with cancer. Taken together, research indicates that combining TRT and ICI might improve therapeutic response in patients with cancer. Future research has to disclose what the optimal conditions are in terms of dose and treatment schedule to maximize the efficacy of this combined approach.
引用
收藏
页码:3652 / 3657
页数:6
相关论文
共 50 条
  • [1] Preclinical evaluation of targeted radionuclide therapy combined with immune checkpoint inhibition
    Oosterwijk, E.
    Kleidendorst, S.
    Konijnenberg, M.
    Merkx, R.
    Twumasi-Boateng, K.
    Chandler, P.
    Wheatcroft, M.
    Heskamp, S.
    Mulders, P. F. A.
    [J]. EUROPEAN UROLOGY, 2023, 83
  • [2] Preclinical evaluation of targeted radionuclide therapy combined with immune checkpoint inhibition
    Kleinendorst, S.
    Konijnenberg, M.
    Merkx, R.
    Twumasi-Boateng, K.
    Chandler, P.
    Wheatcroft, M.
    Oosterwijk, E.
    Heskamp, S.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S58 - S59
  • [3] Combining checkpoint inhibition and targeted therapy in melanoma
    Rozeman, Elisa A.
    Blank, Christian U.
    [J]. NATURE MEDICINE, 2019, 25 (06) : 879 - 882
  • [4] Combining checkpoint inhibition and targeted therapy in melanoma
    Elisa A. Rozeman
    Christian U. Blank
    [J]. Nature Medicine, 2019, 25 : 879 - 882
  • [5] Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
    Teresa Kim
    Rodabe NAmaria
    Christine Spencer
    Alexandre Reuben
    Zachary ACooper
    Jennifer AWargo
    [J]. Cancer Biology & Medicine., 2014, 11 (04) - 246+213
  • [6] Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
    Teresa Kim
    Rodabe N.Amaria
    Christine Spencer
    Alexandre Reuben
    Zachary A.Cooper
    Jennifer A.Wargo
    [J]. Cancer Biology & Medicine, 2014, (04) : 237 - 246
  • [7] In vivo efficacy of bempegaldesleukin, immune checkpoint inhibition, and targeted radionuclide therapy in immunocompetent murine model of head and neck cancer
    Sosa, Gustavo A.
    Bates, Amber M.
    Patel, Ravi
    Hernandez, Reinier
    Grudzinski, Joseph J.
    Marsh, Ian
    Bednarz, Bryan
    Pieper, Alexander
    Nystuen, Erin
    Emma, Sarah
    Sumiec, Elizabeth G.
    Weichert, Jamey P.
    Morris, Zachary S.
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [8] Combining immune checkpoint inhibition and DNA damage repair (DDR) targeted therapy in small cell lung cancer (SCLC)
    Sen, Triparna
    Chen, Limo
    Rodriguez, Bertha Leticia
    Yang, Yongbin
    Fan, You Hong
    Stewart, Catherine Allison
    Glisson, Bonnie
    Piwnica-Worms, Helen
    Sage, Julien
    Heymach, John V.
    Gibbons, Don L.
    Byers, Lauren A.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
  • [9] Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
    Leone, Gian Marco
    Candido, Saverio
    Lavoro, Alessandro
    Vivarelli, Silvia
    Gattuso, Giuseppe
    Calina, Daniela
    Libra, Massimo
    Falzone, Luca
    [J]. PHARMACEUTICS, 2023, 15 (04)
  • [10] Combining targeted therapy and immune checkpoint blockade to improve responses
    Wargo, Jennifer A.
    [J]. CANCER RESEARCH, 2015, 75